title: Fasting glucose and treatment outcome in breast and colorectal cancer patients treated with targeted agents: results from a historic cohort.
abstract: BACKGROUND
  We investigated pretreatment fasting glucose as a predictor of patients' important outcomes in breast and colorectal cancers undergoing targeted therapies.
  
  
  METHODS
  In a historic cohort of 202 breast and 218 colorectal cancers treated with targeted agents from 1998 to 2009, we used the Kaplan-Meier method and the log-rank test to estimate survival through tertiles of fasting glucose and the Cox proportional hazards model for multivariate analysis stratified by primary site of cancer and including gender, age and body mass index.
  
  
  RESULTS
  The median follow-up was 20 months (1-128). At 60 months, 65% of patients in the lowest tertile of fasting glucose did not experiment disease progression compared with 34% in the highest tertile (P=0.001). Seventy-six percent of females in the lowest tertile showed no progression compared with 49% in the top tertiles (P=0.015). In multivariate analysis, fasting glucose was a significant predictor of time to disease progression only in breast cancer patients in the first tertile compared with the third (P=0.017).
  
  
  CONCLUSIONS
  We found evidence of a predictive role of pretreatment fasting glucose in the development of resistance in breast cancer patients treated with targeted agents. Prospective studies are warranted to confirm our findings.
authors.affiliation: Sbarro Institute for Cancer Research and Molecular Medicine, Center for Biotechnology, Temple University, Philadelphia, USA.
authors.forename: M
authors.initials: M
authors.lastname: Barba
authors.forename: F
authors.initials: F
authors.lastname: Sperati
authors.forename: S
authors.initials: S
authors.lastname: Stranges
authors.forename: C
authors.initials: C
authors.lastname: Carlomagno
authors.forename: G
authors.initials: G
authors.lastname: Nasti
authors.forename: V
authors.initials: V
authors.lastname: Iaffaioli
authors.forename: G
authors.initials: G
authors.lastname: Caolo
authors.forename: M
authors.initials: M
authors.lastname: Mottolese
authors.forename: G
authors.initials: G
authors.lastname: Botti
authors.forename: I
authors.initials: I
authors.lastname: Terrenato
authors.forename: P
authors.initials: P
authors.lastname: Vici
authors.forename: D
authors.initials: D
authors.lastname: Serpico
authors.forename: A
authors.initials: A
authors.lastname: Giordano
authors.forename: G
authors.initials: G
authors.lastname: D'Aiuto
authors.forename: A
authors.initials: A
authors.lastname: Crispo
authors.forename: M
authors.initials: M
authors.lastname: Montella
authors.forename: G
authors.initials: G
authors.lastname: Capurso
authors.forename: G
authors.initials: G
authors.lastname: Delle Fave
authors.forename: B
authors.initials: B
authors.lastname: Fuhrman
authors.forename: C
authors.initials: C
authors.lastname: Botti
authors.forename: S
authors.initials: S
authors.lastname: De Placido
mesh_terms: D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000068258:Bevacizumab; D014408:Biomarkers, Tumor / Q000097:blood; D001786:Blood Glucose; D001943:Breast Neoplasms / Q000097:blood / Q000188:drug therapy*; D000068818:Cetuximab; D015179:Colorectal Neoplasms / Q000097:blood / Q000188:drug therapy*; D018572:Disease-Free Survival; D019008:Drug Resistance, Neoplasm; D005215:Fasting; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D058990:Molecular Targeted Therapy; D015999:Multivariate Analysis; D016016:Proportional Hazards Models; D012189:Retrospective Studies; D000068878:Trastuzumab; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D001786:Blood Glucose; D000068258:Bevacizumab; D000068878:Trastuzumab; D000068818:Cetuximab
references.citation: Oncogene. 2002 Apr 25;21(18):2785-96
references.pmid: 11973637
references.citation: Int J Cancer. 2007 Aug 15;121(4):856-62
references.pmid: 17397032
references.citation: Lancet Oncol. 2009 Dec;10(12):1179-87
references.pmid: 19959074
references.citation: Dig Dis Sci. 2005 Mar;50(3):499-505
references.pmid: 15810632
references.citation: J Biol Chem. 2000 Jul 21;275(29):22583-9
references.pmid: 10807918
references.citation: Diabetes Care. 1997;20 Suppl 1:S1-70
references.pmid: 9028710
references.citation: Mol Cell Biol. 1994 Jul;14(7):4588-95
references.pmid: 8007963
references.citation: Cancer Causes Control. 1999 Oct;10(5):379-86
references.pmid: 10530607
references.citation: Cancer Epidemiol Biomarkers Prev. 2002 Apr;11(4):385-91
references.pmid: 11927499
references.citation: Toxicol Appl Pharmacol. 2006 Apr 15;212(2):167-78
references.pmid: 16490224
references.citation: Arch Physiol Biochem. 2008 Feb;114(1):63-70
references.pmid: 18465360
references.citation: JAMA. 2005 Jan 12;293(2):194-202
references.pmid: 15644546
references.citation: Proc Nutr Soc. 2001 Feb;60(1):91-106
references.pmid: 11310428
references.citation: Exp Clin Endocrinol Diabetes. 2010 Jan;118(1):4-8
references.pmid: 20127570
references.citation: J Biol Chem. 1996 Nov 15;271(46):29483-8
references.pmid: 8910616
references.citation: Cancer Epidemiol Biomarkers Prev. 2005 Apr;14(4):850-5
references.pmid: 15824155
references.citation: Eur J Surg Oncol. 2007 Dec;33 Suppl 2:S24-34
references.pmid: 17981431
references.citation: Cancer Epidemiol Biomarkers Prev. 2002 Nov;11(11):1361-8
references.pmid: 12433712
references.citation: Nat Rev Cancer. 2004 Aug;4(8):579-91
references.pmid: 15286738
references.citation: Diabetes. 2003 Nov;52(11):2795-804
references.pmid: 14578299
references.citation: Cancer Epidemiol Biomarkers Prev. 2003 May;12(5):412-8
references.pmid: 12750235
references.citation: J Cell Physiol. 1998 Dec;177(3):387-95
references.pmid: 9808147
references.citation: Gastroenterology. 2007 Nov;133(5):1423-9
references.pmid: 17904132
references.citation: Arch Pathol Lab Med. 2007;131(1):18-43
references.pmid: 19548375
references.citation: Cancer. 2006 Jul 1;107(1):28-36
references.pmid: 16721800
references.citation: Diabetes Care. 2007 Mar;30(3):561-7
references.pmid: 17327321
references.citation: Cancer Epidemiol Biomarkers Prev. 2010 Mar;19(3):850-8
references.pmid: 20200432
references.citation: Br J Cancer. 2001 Feb 2;84(3):417-22
references.pmid: 11161410
references.citation: Clin Gastroenterol Hepatol. 2006 Dec;4(12):1514-21
references.pmid: 17162243
references.citation: J Natl Cancer Inst. 1999 Jul 7;91(13):1147-54
references.pmid: 10393723
references.citation: Cancer Epidemiol Biomarkers Prev. 2006 Apr;15(4):750-5
references.pmid: 16614119
references.citation: Endocrinology. 1996 Jun;137(6):2262-8
references.pmid: 8641174
references.citation: Diabetologia. 2006 May;49(5):945-52
references.pmid: 16557372
references.citation: Adv Clin Chem. 2010;51:71-119
references.pmid: 20857619
references.citation: Cancer Epidemiol Biomarkers Prev. 2001 Sep;10(9):937-41
references.pmid: 11535544
references.citation: J Natl Cancer Inst. 2005 Nov 16;97(22):1679-87
references.pmid: 16288121
references.citation: EMBO J. 1998 Sep 1;17(17):5085-94
references.pmid: 9724644